Navigation Links
MediVet Biologics Acquires Exclusive Patent License from Kansas State University

MediVet Biologics today announced that it has acquired US PATENT 7736892 B2. Under the terms of the agreement, MediVet will acquire the rights to a portfolio of cultures, products and methods using Umbilical Cord Matrix Stem Cells (UCMSCs). MB-007 is currently in pre-clinical development as a potential next-generation treatment for various musculoskeletal and internal medicine conditions for mammalian species.

“Our mission as a company has always been to provide novel treatments at an affordable cost to the marketplace. Our entire team is excited to make this announcement and acquire a strong partner in Dr. Mark Weiss and his team at Kansas State University. MediVet Biologics envisions this product as an additional modality for our growing progressive network of Veterinarians at the general practice and specialty levels. We feel this strengthens our portfolio of cellular therapy modalities and allows us to further expand to meet unmet needs in the market. The shifting economic dynamics in the market provides us confidence Veterinary medical professionals are seeking good medicine based in science with potential strong brick and mortar impact,” said MediVet Biologics CEO Jeremy Delk.

According to Mark Weiss, PhD, Inventor of MB-007 and Professor at Kansas State University College of Veterinary Medicine, “this agreement was undertaken due to confidence we have and track record MediVet Biologics has proven in the Veterinary market. We share a mission of basing research initiatives to advance cellular therapy in the human and animal markets.” Dr. Weiss currently serves as Director of Cell Biology for MediVet Biologics.

“To date our team has made excellent progress in our MB-007 research at KSU. The product and technology will be versatile to target disease specific processes for a variety of species.”

About MB-007:

Stem cells derivative of adult sources can have a variety of useful applications in disease treatment and biotechnology. More particularly the Umbilical Cord Matrix Stem Cells (UCMSCs) of the invention have a variety of pluripotent, or multipotent capabilities for a variety of end uses from a non-controversial, universally available, species-specific source. MB-007 can have application to any mammalian animal including canines, felines and equine patients. MB-007 relates to isolating the stem cells, culturing the stem cells, maintaining the stem cells, transforming the stem cells into useful cell types using genetic or other transformation technologies, stem cell and tissue banking and using untransformed or transformed cells in disease treatment. The goal of the partnership is to advance MB-007 and other promising biologic candidates to ultimately provide novel therapies for musculoskeletal and internal medicine conditions and other diseases and disorders.

About MediVet Biologics:

MediVet Biologics is a global leader in veterinary regenerative medicine and biological solutions. With corporate offices in Central, Kentucky, and Sydney, Australia and cases performed in over 29 countries around the world. MediVet’s accomplishments in the regenerative medicine market have given way to an incredible pipeline of technological advancements and the ability to successfully bring those animal health products to market. MediVet is the only Veterinary Regenerative Medicine Company to have multiple collaborative university studies further validating current technology and product pipelines. MediVet prides itself on having the latest cutting edge technologies to allow Veterinarians the ability to ease their patient’s pain. To learn more about MediVet Biologics, call 1.800.365.9168 or visit us at

Read the full story at

Source: PRWeb
Copyright©2015 Vocus, Inc.
All rights reserved

Related biology technology :

1. MediVet Biologics adds Merritt Veterinary Supplies, Inc. as a Distribution Partner of Veterinary Stem Cell and other Biologic treatment options.
2. MediVet Biologics to Host Progressive Summit on Animal Health Biologic Treatment Options at 2015 AVMA Convention in Boston
3. World’s first tendon replacement using Nanofiber and activated MediVet Stem Cell Fraction
4. MediVet America Secures Exclusive Worldwide License with Nanofiber Veterinary
5. Subcutaneous Biologics: Products, Technologies and Delivery Systems
6. First Participant Dosed in Synthetic Biologics Second Phase 2a Clinical Trial to Protect the Microbiome and Prevent C. difficile
7. Baxter Ventures, Mayo Clinic And Velocity Pharmaceutical Development Announce The Formation Of Vitesse Biologics, LLC, A Company Structured To Accelerate Therapeutic Innovation
8. Maureen Early Named Vice President, Commercial of Synthetic Biologics
9. Bone Biologics Corp Completes Financing With Hankey Capital, LLC
10. Turnstone Biologics Inc. to accelerate clinical and commercial translation of cancer immunotherapies
11. Genedata Biologics 5.0 – Antibody Engineering and Developability Assessment Advances
Post Your Comments:
(Date:6/23/2020)... Ore. (PRWEB) , ... June 23, 2020 , ... ... of innovative CNS therapies, today announced that it has filed an Investigational New ... a Phase 2b clinical trial of its lead drug candidate NBTX-001 in patients ...
(Date:6/11/2020)... GREENBELT, Md. (PRWEB) , ... June 09, 2020 ... ... announced today the release of the NEON Micro-Tracer Solution, a highly ... to the COVID-19 virus in the workplace. Contact tracing, a core disease control ...
(Date:5/30/2020)... ... May 29, 2020 , ... Medrio, Inc., the ... health markets, has enabled Cytovale, Inc., a medical technology company dedicated to revolutionizing ... achieve their first patient in (FPI) in just seven days. The Cytovale technology ...
(Date:5/26/2020)... PARK, Calif. (PRWEB) , ... May 26, 2020 , ... ... , the most recognized brand of smart garage door openers, announce a new integration ... line of Wi-Fi enabled garage door openers powered by Aladdin Connect® can now be ...
Breaking Biology Technology:
(Date:6/28/2020)... ... June 25, 2020 , ... Genedata, ... that it has entered into a multi-year contract with Merus N.V., a ... translational and clinical research strategy to discover and develop ground-breaking drugs. The ...
(Date:6/25/2020)... ... June 24, 2020 , ... eClinical Solutions LLC ... services that accelerate drug development, is collaborating with Karyopharm Therapeutics (Nasdaq: KPTI ... patients with severe COVID-19. This is the first study of an XPO1 inhibitor ...
(Date:6/23/2020)... ... June 23, 2020 , ... First Aid Africa, a ... UK supplier and manufacturer of innovative portable renewable energy equipment, have announced the ... against the COVID-19 pandemic in Zambia. , One of Renovagen’s FAST FOLD portable ...
Breaking Biology News(10 mins):